Moderna (MRNA) Cash & Current Investments (2016 - 2026)

Moderna (MRNA) has 11 years of Cash & Current Investments data on file, last reported at $5.2 billion in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $5.2 billion, down 12.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 billion (down 12.89% YoY), and the FY2025 annual result was $5.8 billion, down 17.45% from the prior year.
• Cash & Current Investments slipped to $5.2 billion in Q1 2026 per MRNA's latest filing, from $5.8 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $10.1 billion in Q1 2022 and troughed at $4.5 billion in Q3 2025.
• A 5-year average of $7.5 billion and a median of $7.9 billion in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments surged 30.77% in 2022, then sank 39.55% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $9.9 billion in 2022, then slipped by 13.11% to $8.6 billion in 2023, then decreased by 18.35% to $7.0 billion in 2024, then declined by 17.45% to $5.8 billion in 2025, then fell by 10.24% to $5.2 billion in 2026.
• Business Quant data shows MRNA's Cash & Current Investments at $5.2 billion in Q1 2026, $5.8 billion in Q4 2025, and $4.5 billion in Q3 2025.